A Safety Perspective on Additional Aspects of Drug Development and Therapeutic Use

  • J. Rick Turner
  • Dilip R. Karnad
  • Snehal Kothari


Previous chapters have focused on cardiovascular safety in drug development and therapeutic use. In this final chapter, we provide a flavor of safety considerations in other aspects of integrated biopharmaceutical medicine, a discipline that encompasses drug development, commercial-scale manufacture, prescription by physicians, dispensing by pharmacists, and the administration of medicines (both by patients themselves and by caretakers, hospital staff, and residential care staff).


Allergic Rhinitis Anaplastic Lymphoma Kinase Orphan Drug Medical Expenditure Panel Survey Prescription Opioid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M (2012) A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 26:50–60PubMedPubMedCentralCrossRefGoogle Scholar
  2. Alexander L, Mannion RO, Weingarten B, Fanelli RJ, Stiles GL (2014) Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend 138:1–6PubMedCrossRefGoogle Scholar
  3. Altman DF, Schulz KF, Moher D (2001) Turning a blind eye: testing the success of blinding and the CONSORT statement. BMJ 328:1135CrossRefGoogle Scholar
  4. American Heart Association (2016) Medication adherence: taking your meds as directed. Available at: Accessed 1 Jan 2016
  5. Balu S (2009) Estimated annual direct expenditures in the United States as a result of inappropriate hypertension treatment according to national treatment guidelines. Clin Ther 31:1581–1594PubMedCrossRefGoogle Scholar
  6. Begg C, Cho M, Eastwood S et al (1996) Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 276:637–639PubMedCrossRefGoogle Scholar
  7. Bender BG (2015) Motivating patient adherence to allergic rhinitis treatments. Curr Allergy Asthma Rep 15:10PubMedCrossRefGoogle Scholar
  8. Brown MT, Bussell JK (2011) Medication adherence: WHO cares? Mayo Clin Proc 86:304–314PubMedPubMedCentralCrossRefGoogle Scholar
  9. Cabana MD, Rand CS, Powe NR et al (1999) Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 282:1458–1465PubMedCrossRefGoogle Scholar
  10. Califf RM, Woodcock J, Ostroff S (2016) A proactive response to prescription opioid abuse. N Engl J Med 374(15):1480–1485PubMedCrossRefGoogle Scholar
  11. Centers for Disease Control and Prevention (CDC) (2014) Web-based injury statistics query and reporting system (WISQARS). Available at: Accessed 19 Mar 2016
  12. Cloutier C, Taliano J, O’Mahony W et al (2013) Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. Pain Res Manag 18:75–82PubMedPubMedCentralCrossRefGoogle Scholar
  13. Consort Group (2016) Consort statement: transparent reporting of trials. Available at: Accessed 1 Jan 2016
  14. Dennis BB, Bawor M, Paul J et al (2015) The impact of chronic pain on opioid addiction treatment: a systematic review protocol. Syst Rev 4:49PubMedPubMedCentralCrossRefGoogle Scholar
  15. Dolan E, O’Brien E. Hypertension – the major cause of death and morbidity worldwide; where are our policy makers? Irish Medical Times. 25 Jan 2013. p 33Google Scholar
  16. Earley A, Lau J, Uhlig K (2013) Haphazard reporting of deaths in clinical trials: a review of cases of records and matched publications-a cross-sectional study. BMJ Open 3:e001963PubMedPubMedCentralCrossRefGoogle Scholar
  17. FDA (2004) Innovation or stagnation: challenge and opportunity on the critical path to new medical products. Accessed 1 Jan 2016
  18. FDA (2008) The sentinel initiative: national strategy for monitoring medical product safety. May 2008. Available at: Accessed 23 Nov 2015
  19. FDA (2011) Advancing regulatory science at FDA: a strategic plan. August 2011. Available at: Accessed 1 Feb 2016
  20. FDA (2015a) Novel new drug 2014 summary. January 2015. Available at: Accessed 1 Jan 2016
  21. FDA (2015b) Guidance for industry. Abuse-deterrent opioids: evaluation and labeling. April 2015. Available at: Accessed 1 Jan 2016
  22. FDA (2015c) Safe use initiative. Available at: Accessed 1Jan 2016
  23. FDA (2016) Novel new drug 2015 summary. January 2016. Available at: Accessed 14 Feb 2014
  24. Goldman M, Seigneuret N, Eichler HG (2015) The Innovative Medicines Initiative: an engine for regulatory science. Nat Rev Drug Discov 14:1–2PubMedCrossRefGoogle Scholar
  25. Hamburg MA (2010) Remarks at the National Press Club speaker luncheon. 6 Oct 2010. Available at: Accessed 1 Feb 2016
  26. Hartung DM, Zarin DA, Guise JM et al (2014) Reporting discrepancies between the results database and peer-reviewed publications. Ann Intern Med 160:477–483PubMedPubMedCentralCrossRefGoogle Scholar
  27. Herzig SJ (2015) Growing concerns regarding long-term opioid use: the hospitalization hazard. J Hosp Med 10:469–470PubMedPubMedCentralCrossRefGoogle Scholar
  28. Howren MB (2013) Adherence. In: Gellman MD, Turner JR (eds) Encyclopedia of behavioral medicine. Springer, New York, pp 33–39Google Scholar
  29. Ingelman-Sundberg M (2008) Pharmacogenetic biomarkers for prediction of severe adverse drug reactions. New Engl J Med 358:637–639PubMedCrossRefGoogle Scholar
  30. Ioannidis JP, Evans SJ, Gotzsche PC et al (2004) Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141:781–788PubMedCrossRefGoogle Scholar
  31. Joffe AM, Hallman M, Gélinas C, Herr DL, Puntillo K (2013) Evaluation and treatment of pain in critically ill adults. Semin Respir Crit Care Med 34:189–200PubMedCrossRefGoogle Scholar
  32. Kaitin KI (2008) Obstacles and opportunities in new drug development. Clin Pharmacol Ther 83:210–212PubMedCrossRefGoogle Scholar
  33. Katz DL (2001) Clinical epidemiology & evidence-based medicine: fundamental principles of clinical reasoning and research. Sage Publications, Thousand OaksGoogle Scholar
  34. Korsch BM, Gozzi EK, Francis V (1968) Gaps in doctor-patient communication. 1. Doctor-patient interaction and patient satisfaction. Pediatrics 42:855–871PubMedGoogle Scholar
  35. Lee J, Turner JR (2016) Raising the bar in renal denervation research and reporting. J Clin Hypertens (Greenwich) 18:89–94CrossRefGoogle Scholar
  36. Levinson W, Lesser CS, Epstein RM (2010) Developing physician communication skills for patient-centered care. Health Aff (Millwood) 29:1310–1318CrossRefGoogle Scholar
  37. Maggi CB, Griebeler IH, da Silva Dal Pizzol T (2014) Information on adverse events in randomised clinical trials assessing drug interventions published in four medical journals with high impact factors. Int J Risk Saf Med 26:9–22PubMedGoogle Scholar
  38. Magin P, Victoire A, Zhen XM et al (2013) Under-reporting of socioeconomic status of patients in stroke trials: adherence to CONSORT principles. Stroke 44:2920–2922PubMedPubMedCentralCrossRefGoogle Scholar
  39. Mallal S, Phillips E, Carosi G, PREDICT-1 Study Team et al (2008) HLA*B5701 screening for hypersensitivity to abacavir. New Engl J Med 358:568–579Google Scholar
  40. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G (2010) Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 126:969–975PubMedCrossRefGoogle Scholar
  41. Mastropietro DJ, Omidian H (2015) Abuse-deterrent formulations: Part 2: commercial products and proprietary technologies. Expert Opin Pharmacother 2015;16:305–323Google Scholar
  42. Meyer RJ (2014) The role of academic medical centers in advancing regulatory science. Clin Pharmacol Ther 95:471–473Google Scholar
  43. Moher D, Schulz KF, Altman DG, CONSORT Group (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191–1194PubMedCrossRefGoogle Scholar
  44. Moher D, Hopewell S, Schulz KF et al (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340:c869PubMedPubMedCentralCrossRefGoogle Scholar
  45. Nieuwlaat R, Schwalm JD, Khatib R, Yusuf S (2013) Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J 34:1262–1269PubMedCrossRefGoogle Scholar
  46. Pasternak GW, Pan YX (2013) Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 65:1257–1317PubMedPubMedCentralCrossRefGoogle Scholar
  47. Prud’homme M, Cata R, Jutras-Aswad D (2015) Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Subst Abuse 9:33–38PubMedPubMedCentralGoogle Scholar
  48. Reed K, Day E, Keen J, Strang J (2015) Pharmacological treatments for drug misuse and dependence. Expert Opin Pharmacother 16:325–333PubMedGoogle Scholar
  49. Richards AL, Turner JR (2012) The moral imperative of improving patient adherence to pharmacotherapy for cardiodiabesity, Part II: a focus on cardiovascular disease. J Patient Compliance 2(2):36–41Google Scholar
  50. Riveros C, Dechartres A, Perrodeau E et al (2013) Timing and completeness of trial results posted at and published in journals. PLoS Med 10:e1001566PubMedPubMedCentralCrossRefGoogle Scholar
  51. Rose L, Haslam L, Dale C, Knechtel L, McGillion M (2013) Behavioral pain assessment tool for critically ill adults unable to self-report pain. Am J Crit Care 22:246–255PubMedCrossRefGoogle Scholar
  52. Roter D, Hall JA (2013) Doctor-patient communication: why and how communication contributes to the quality of medical care. In: Gellman MD, Turner JR (eds) Encyclopedia of behavioral medicine. Springer, New York, pp 622–627Google Scholar
  53. Runguphan W, Glenn WS, O’Connor SE (2012) Redesign of a dioxygenase in morphine biosynthesis. Chem Biol 19:674–678PubMedCrossRefGoogle Scholar
  54. Sasinowski FJ, Panico EB, Valentine JE (2015) Quantum of effectiveness evidence in FDA’s approval of orphan drugs: update, July 2010 to June 2014. Therap Innov Regul Sci 49:680–697CrossRefGoogle Scholar
  55. Schedlbauer A, Davies P, Fahey T (2010) Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 3:CD004371Google Scholar
  56. Seidman MD, Gurgel RK, Lin SY, Guideline Otolaryngology Development Group et al (2015) AAO-HNSF. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg 152(1 Suppl):S1–S43Google Scholar
  57. Sivendran S, Latif A, McBride RB et al (2014) Adverse event reporting in cancer clinical trial publications. J Clin Oncol 32:83–89PubMedCrossRefGoogle Scholar
  58. Soyka M (2015) New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil 6:1–14PubMedPubMedCentralCrossRefGoogle Scholar
  59. Steinbrook R (2004) Public registration of clinical trials. New Engl J Med 351:315–317PubMedCrossRefGoogle Scholar
  60. Tang E, Ravaud P, Riveros C, Perrodeau E, Dechartres A (2015) Comparison of serious adverse events posted at and published in corresponding journal articles. BMC Med 13Google Scholar
  61. Trenkwalder C, Beneš H, Grote L, RELOXYN Study Group et al (2013) Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 12:1141–1150Google Scholar
  62. Turner JR (2012a) Editor’s Comment accompanying the following paper: Sasinowski FJ. Quantum of effectiveness evidence in FDA’s approval of orphan drugs: cataloguing FDA’s flexibility in regulating therapies for persons with rare disorders. Drug Info J 46:238–263Google Scholar
  63. Turner JR (2012b) Translational cardiovascular safety: a primer of nonclinical investigations for clinical scientists. J Clini Studies 4(1):50–61Google Scholar
  64. Turner JR (2013) Patient and physician adherence in hypertension management. J Clin Hypertens (Greenwich) 15:447–452CrossRefGoogle Scholar
  65. Turner JR, Durham TA (2009) Integrated cardiac safety: assessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance. Wiley, HobokenGoogle Scholar
  66. Turner JR, Strumph P (2012) The moral imperative of improving patient adherence to pharmacotherapy for cardiodiabesity, Part I: a focus on type 2 diabetes mellitus. J Patient Compliance 2(1):32–36Google Scholar
  67. Woodcock J (2014) Paving the critical path of drug development: the CDER perspective. Nat Rev Drug Discov 13:783–784Google Scholar
  68. Woodcock J, Brumfield M, Gill D, Zerhouni E (2014) The driving role of consortia on the critical path to innovative therapies. Nat Rev Drug Discov 13:781PubMedCrossRefGoogle Scholar

Further Readings by Topic

  1. In this chapter the Further Reading list is broken into seven sections. The first six address the topics discussed in the text of the chapter, and the seventh provides publications addressing a multitude of other topics in the expansive realm of integrated pharmaceutical medicine.Google Scholar

Regulatory Science

  1. Borup G, Bach KF, Schmiegelow M et al (2016) A paradigm shift towards patient involvement in medicines development and regulatory science: workshop proceedings and commentary. Ther Innovat Regul Sci 50:304–311Google Scholar
  2. Geanacopoulos M, Barratt R (2015) How the critical path initiative addresses CDER’s regulatory science needs: some illustrative examples. Ther Innovat Regul Sci 49:466–472CrossRefGoogle Scholar
  3. Gispen-de Wied CC, Leufkens HG (2013) From molecule to market access: drug regulatory science as an upcoming discipline. Eur J Pharmacol 719:9–15PubMedCrossRefGoogle Scholar
  4. Liang Z, Mao Q, Wang Y et al (2014) Regulatory science accelerates the development of biotechnology drugs and vaccines by NIFDC. Emerg Microbes Infect 3:e67PubMedPubMedCentralCrossRefGoogle Scholar
  5. Lumpkin MM, Eichler HG, Breckenridge A et al (2012) Advancing the science of medicines regulation: the role of the 21st-century medicines regulator. Clin Pharmacol Ther 92:486–493PubMedGoogle Scholar
  6. McCune SK, Mulugeta YA (2014) Regulatory science needs for neonates: a call for neonatal community collaboration and innovation. Front Pediatr 2:135PubMedPubMedCentralCrossRefGoogle Scholar
  7. Offringa M, Davis JM, Turner MA et al (2015) Applying regulatory science to develop safe and effective medicines for neonates: report of the US Food and Drug Administration First Annual Neonatal Scientific Workshop, October 28–29, 2014. Ther Innov Regul Sci 49:623–631Google Scholar
  8. Patel M, Miller MA (2012) Impact of regulatory science on global public health. Kaohsiung J Med Sci 28(7 Suppl):S5–S9PubMedCrossRefGoogle Scholar
  9. Slikker W Jr, Miller MA, Lou Valdez M, Hamburg MA (2012) Advancing global health through regulatory science research: summary of the Global Summit on Regulatory Science Research and Innovation. Regul Toxicol Pharmacol 62:471–473PubMedCrossRefGoogle Scholar
  10. Spielberg SP (2015) Multifaceted paths toward advancing regulatory science. Ther Innovat Regul Sci 49:465CrossRefGoogle Scholar
  11. Spindler P, Bach KF, Schmiegelow M, Bedlington N, Eichler H-G (2016) Innovation of medical products: the evolution of regulatory science, research, and education. Ther Innovat Regul Sci 50:44–48CrossRefGoogle Scholar
  12. Zineh I, Woodcock J (2013) Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation. Clin Pharmacol Ther 93:515–525PubMedCrossRefGoogle Scholar

Rare Diseases

  1. Billingham L, Malottki K, Steven N (2016) Research methods to change clinical practice for patients with rare cancers. Lancet Oncol 17:e70–e80PubMedCrossRefGoogle Scholar
  2. Drummond M, Towse A (2014) Orphan drugs policies: a suitable case for treatment. Eur J Health Econ 15:335–340PubMedCrossRefGoogle Scholar
  3. Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ (2014) World health dilemmas: orphan and rare diseases, orphan drugs and orphan patients. World J Methodol 4:163–188PubMedPubMedCentralCrossRefGoogle Scholar
  4. Kumar Kakkar A, Dahiya N (2014) The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space. Drug Dev Res 75:231–234PubMedCrossRefGoogle Scholar
  5. Logviss K, Krievins D, Purvina S (2014) Rare diseases and orphan drugs: Latvian story. Orphanet J Rare Dis 9:147PubMedPubMedCentralCrossRefGoogle Scholar
  6. Pastores GM, Gupta P (2013) Orphan drug development. Pediatr Endocrinol Rev 11(Suppl 1):64–67PubMedGoogle Scholar
  7. Patra K, Cree BAC, Katz E et al (2016) Statistical considerations for an adaptive design for a serious rare disease. Ther Innovat Regul Sci 50:375–384Google Scholar
  8. Paulden M, Stafinski T, Menon D, McCabe C (2015) Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics 33:255–269PubMedCrossRefGoogle Scholar
  9. Reardon S (2014) Regulators adopt more orphan drugs. Nature 508:16–17PubMedCrossRefGoogle Scholar
  10. Schey C, Milanova T, Hutchings A (2011) Estimating the budget impact of orphan medicines in Europe: 2010–2020. Orphanet J Rare Dis 6:62PubMedPubMedCentralCrossRefGoogle Scholar
  11. Woodcock J (2012) The future of orphan drug development. Clin Pharmacol Ther 92:146–148PubMedCrossRefGoogle Scholar

Precision Medicine

  1. Amable L (2016) Cisplatin resistance and opportunities for precision medicine. Pharmacol Res 106:27–36PubMedCrossRefGoogle Scholar
  2. Arnedos M, Vicier C, Loi S et al (2015) Precision medicine for metastatic breast cancer: limitations and solutions. Nat Rev Clin Oncol 12:693–704. Jul 21PubMedCrossRefGoogle Scholar
  3. Auffray C, Caulfield T, Griffin JL et al (2016) From genomic medicine to precision medicine: highlights of 2015. Genome Med 8:12PubMedPubMedCentralCrossRefGoogle Scholar
  4. Bauer C, Stec K, Glintschert A et al (2015) BioMiner: paving the way for personalized medicine. Cancer Inform 14:55–63PubMedPubMedCentralCrossRefGoogle Scholar
  5. Bermejo-Martin JF, Andaluz-Ojeda D, Almansa R et al (2016) Defining immunological dysfunction in sepsis: a requisite tool for precision medicine. J Infect 72(5):525–536PubMedCrossRefGoogle Scholar
  6. Bu LL, Yang K, Xiong WX et al (2016) Toward precision medicine in Parkinson’s disease. Ann Transl Med 4:26PubMedPubMedCentralCrossRefGoogle Scholar
  7. Hasler G, Wolf A (2015) Toward stratified treatments for bipolar disorders. Eur Neuropsychopharmacol 25:283–294PubMedCrossRefGoogle Scholar
  8. Heckman-Stoddard BM, Smith JJ (2014) Precision medicine clinical trials: defining new treatment strategies. Semin Oncol Nurs 30:109–116PubMedPubMedCentralCrossRefGoogle Scholar
  9. Irwin MS, Park JR (2015) Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am 62:225–256PubMedCrossRefGoogle Scholar
  10. Johnson JA, Cavallari LH (2013) Pharmacogenetics and cardiovascular disease: implications for personalized medicine. Pharmacol Rev 65:987–1009PubMedPubMedCentralCrossRefGoogle Scholar
  11. Kirchhof P, Sipido KR, Cowie MR, ESC CRT R&D and European Affairs Work Shop on Personalized Medicine et al (2014) The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J 35:3250–3257PubMedPubMedCentralCrossRefGoogle Scholar
  12. Kovacs GG (2016) Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine. Int J Mol Sci 17:e189PubMedCrossRefGoogle Scholar
  13. Lemoine C (2014) Precision medicine for nurses: 101. Semin Oncol Nurs 30:84–99PubMedCrossRefGoogle Scholar
  14. McNeil C (2015) NCI-MATCH launch highlights new trial design in precision-medicine era. J Natl Cancer Inst 107:193CrossRefGoogle Scholar
  15. Montine TJ, Montine KS (2015) Precision medicine: clarity for the clinical and biological complexity of Alzheimer’s and Parkinson’s diseases. J Exp Med 212:601–605PubMedPubMedCentralCrossRefGoogle Scholar
  16. Ortega VE, Meyers DA, Bleecker ER (2015) Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. Pharmgenomics Pers Med 8:9–22PubMedPubMedCentralGoogle Scholar
  17. Prados MD, Byron SA, Tran NL et al (2015) Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol 17:1051–1063PubMedPubMedCentralCrossRefGoogle Scholar
  18. Prasad V, Fojo T, Brada M (2016) Precision oncology: origins, optimism, and potential. Lancet Oncol 17:e81–e86PubMedCrossRefGoogle Scholar
  19. Roper N, Stensland KD, Hendricks R, Galsky MD (2015) The landscape of precision cancer medicine clinical trials in the United States. Cancer Treat Rev 41:385–390PubMedCrossRefGoogle Scholar
  20. Williams JK, Katapodi MC, Starkweather A et al (2016) Advanced nursing practice and research contributions to precision medicine. Nurs Outlook 64:117–123PubMedCrossRefGoogle Scholar
  21. Woodcock J (2016) “Precision” drug development? Clin Pharmacol Ther 99:152–154PubMedCrossRefGoogle Scholar
  22. Zou ZY, Liu CY, Che CH, Huang HP (2016) Toward precision medicine in amyotrophic lateral sclerosis. Ann Transl Med 4:27PubMedPubMedCentralCrossRefGoogle Scholar

Pain Medication

  1. Adenuga P, Brown M, Reed D, Guyuron B (2014) Impact of preoperative narcotic use on outcomes in migraine surgery. Plast Reconstr Surg 134:113–119PubMedCrossRefGoogle Scholar
  2. Buchbinder M, Wilbur R, McLean S, Sleath B (2015) Is there any way I can get something for my pain? Patient strategies for requesting analgesics. Patient Educ Couns 98:137–143PubMedCrossRefGoogle Scholar
  3. Cheatle MD (2015) Prescription opioid misuse, abuse, morbidity, and mortality: balancing effective pain management and safety. Pain Med 16(Suppl 1):S3–S8PubMedCrossRefGoogle Scholar
  4. Cicero TJ, Ellis MS (2015) Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from oxycontin. JAMA Psychiatry 72:424–430PubMedCrossRefGoogle Scholar
  5. Costello M (2015) Prescription opioid analgesics: promoting patient safety with better patient education. Am J Nurs 115:50–56PubMedCrossRefGoogle Scholar
  6. Gasior M, Bond M, Malamut R (2016) Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgrad Med 128:85–96PubMedCrossRefGoogle Scholar
  7. Gastfriend DR (2014) A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders. Ann N Y Acad Sci 1327:112–130PubMedPubMedCentralGoogle Scholar
  8. Islam MM, McRae IS (2014) An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions. BMC Pharmacol Toxicol 15:46PubMedPubMedCentralCrossRefGoogle Scholar
  9. Kilaru AS, Gadsden SM, Perrone J et al (2014) How do physicians adopt and apply opioid prescription guidelines in the emergency department? A qualitative study. Ann Emerg Med 64:482–489.e1PubMedPubMedCentralCrossRefGoogle Scholar
  10. Kolodny A, Courtwright DT, Hwang CS et al (2015) The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health 36:559–574PubMedCrossRefGoogle Scholar
  11. Manchikanti L, Atluri S, Candido KD et al (2014) Zohydro approval by food and drug administration: controversial or frightening? Pain Physician 17:E437–E450PubMedGoogle Scholar
  12. Mason JW, Schwertschlag US, Klutzaritz V, Canafax DM (2014) Electrocardiographic and cardiovascular diagnostic characteristics of patients receiving long-term opioid therapy for pain. J Opioid Manag 10:103–109PubMedCrossRefGoogle Scholar
  13. Mastropietro DJ, Omidian H (2015b) Abuse-deterrent formulations: Part 1 – development of a formulation-based classification system. Expert Opin Drug Metab Toxicol 11:193–204PubMedCrossRefGoogle Scholar
  14. Meyer M (2014) The perils of opioid prescribing during pregnancy. Obstet Gynecol Clin North Am 41:297–306Google Scholar
  15. Naing C, Aung K, Racloz V, Yeoh PN (2013) Safety and efficacy of transdermal buprenorphine for the relief of cancer pain. J Cancer Res Clin Oncol 139:1963–1970PubMedCrossRefGoogle Scholar
  16. Nelson LS, Perrone J, Juurlink DN (2014) Painful decision-making at FDA. Expert Opin Drug Saf 13:407–410PubMedCrossRefGoogle Scholar
  17. Passik SD (2014) Tamper-resistant opioid formulations in the treatment of acute pain. Adv Ther 31:264–275PubMedCrossRefGoogle Scholar
  18. Pergolizzi JV Jr, Taylor R Jr, Raffa RB (2015) The potential role of an extended-release, abuse-deterrent oxycodone/acetaminophen fixed-dose combination product for the treatment of acute pain. Adv Ther 32:485–495PubMedPubMedCentralCrossRefGoogle Scholar
  19. Perrone J, Nelson LS (2012) Medication reconciliation for controlled substances: an “ideal” prescription-drug monitoring program. N Engl J Med 366:2341–2343PubMedCrossRefGoogle Scholar
  20. Vowles KE, McEntee ML, Julnes PS et al (2015) Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 156:569–576PubMedCrossRefGoogle Scholar
  21. Weiner SG, Perrone J, Nelson LS (2013) Centering the pendulum: the evolution of emergency medicine opioid prescribing guidelines. Ann Emerg Med 62:241–243PubMedCrossRefGoogle Scholar
  22. Xu X, Gupta A, Al-Ghabeish M, Calderon SN, Khan MA (2016) Risk based in vitro performance assessment of extended release abuse deterrent formulations. Int J Pharm 500:255–267PubMedPubMedCentralCrossRefGoogle Scholar


  1. Bartlett Ellis RJ, Carmon AF, Pike C (2016) A review of immediacy and implications for provider-patient relationships to support medication management. Patient Prefer Adherence 10:9–18PubMedPubMedCentralCrossRefGoogle Scholar
  2. Ceral J, Habrdova V, Vorisek V et al (2011) Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res 34:87–90PubMedCrossRefGoogle Scholar
  3. Chen HY, Saczynski JS, Lapane KL, Kiefe CI, Goldberg RJ (2015) Adherence to evidence-based secondary prevention pharmacotherapy in patients after an acute coronary syndrome: a systematic review. Heart Lung 44:299–308PubMedCrossRefGoogle Scholar
  4. Cheng K, Ingram N, Keenan J, Choudhury RP (2015) Evidence of poor adherence to secondary prevention after acute coronary syndromes: possible remedies through the application of new technologies. Open Heart 2:e000166PubMedPubMedCentralCrossRefGoogle Scholar
  5. Conn VS, Ruppar TM, Chan KC et al (2015a) Packaging interventions to increase medication adherence: systematic review and meta-analysis. Curr Med Res Opin 31:145–160PubMedCrossRefGoogle Scholar
  6. Conn VS, Ruppar TM, Enriquez M, Cooper PS, Chan KC (2015b) Healthcare provider targeted interventions to improve medication adherence: systematic review and meta-analysis. Int J Clin Pract 69:889–899PubMedPubMedCentralCrossRefGoogle Scholar
  7. Foot H, La Caze A, Gujral G, Cottrell N (2016) The necessity-concerns framework predicts adherence to medication in multiple illness conditions: a meta-analysis. Patient Educ Couns 99(5):706–717PubMedCrossRefGoogle Scholar
  8. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2:CD000011Google Scholar
  9. Ho PM, Lambert-Kerzner A, Carey EP et al (2014) Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern Med 174:186–193PubMedCrossRefGoogle Scholar
  10. Ho SC, Chong HY, Chaiyakunapruk N, Tangiisuran B, Jacob SA (2016) Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: a systematic review. J Affect Disord 193:1–10PubMedCrossRefGoogle Scholar
  11. Hollands GJ, McDermott MS, Lindson-Hawley N et al (2015) Interventions to increase adherence to medications for tobacco dependence. Cochrane Database Syst Rev 2:CD009164Google Scholar
  12. Jung O, Gechter JL, Wunder C et al (2013) Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 31:766–774PubMedCrossRefGoogle Scholar
  13. Khatib R, Schwalm JD, Yusuf S et al (2014) Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLoS One 9:e84238PubMedPubMedCentralCrossRefGoogle Scholar
  14. Lambert-Kerzner A, Havranek EP, Plomondon ME et al (2015) Perspectives of patients on factors relating to adherence to post-acute coronary syndrome medical regimens. Patient Prefer Adherence 9:1053–1059PubMedPubMedCentralCrossRefGoogle Scholar
  15. Leporini C, De Sarro G, Russo E (2014) Adherence to therapy and adverse drug reactions: is there a link? Expert Opin Drug Saf 13(Suppl 1):S41–S55Google Scholar
  16. MacDonald L, Chapman S, Syrett M, Bowskill R, Horne R (2016) Improving medication adherence in bipolar disorder: a systematic review and meta-analysis of 30 years of intervention trials. J Affect Disord 194:202–221PubMedCrossRefGoogle Scholar
  17. Mbuagbaw L, Sivaramalingam B, Navarro T, Patient Adherence Review (PAR) Team et al (2015) Interventions for enhancing adherence to antiretroviral therapy (ART): a systematic review of high quality studies. AIDS Patient Care STDS 29:248–266Google Scholar
  18. Paterson M, Kinnear M, Bond C, McKinstry B (2016) A systematic review of electronic multi-compartment medication devices with reminder systems for improving adherence to self-administered medications. Int J Pharm Pract. doi: 10.1111/ijpp.12242 PubMedGoogle Scholar
  19. Pérez-Escamilla B, Franco-Trigo L, Moullin JC, Martínez-Martínez F, García-Corpas JP (2015) Identification of validated questionnaires to measure adherence to pharmacological antihypertensive treatments. Patient Prefer Adherence 9:569–578PubMedPubMedCentralCrossRefGoogle Scholar
  20. Ryan R, Santesso N, Lowe D et al (2014) Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. Cochrane Database Syst Rev 4:CD007768Google Scholar
  21. Smith SG, Sestak I, Forster A et al (2015a) Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol 27(4):575–590PubMedPubMedCentralCrossRefGoogle Scholar
  22. Spoelstra SL, Schueller M, Hilton M, Ridenour K (2015) Interventions combining motivational interviewing and cognitive behaviour to promote medication adherence: a literature review. J Clin Nurs 24:1163–1173PubMedCrossRefGoogle Scholar
  23. Tajouri TH, Driver SL, Holmes DR Jr (2014) ‘Take as directed’ – strategies to improve adherence to cardiac medication. Nat Rev Cardiol 11:304–307PubMedGoogle Scholar
  24. Teeter BS, Kavookjian J (2014) Telephone-based motivational interviewing for medication adherence: a systematic review. Transl Behav Med 4:372–381PubMedPubMedCentralCrossRefGoogle Scholar
  25. Timmerman L, Stronks DL, Groeneweg JG, Huygen FJ (2016) Prevalence and determinants of medication non-adherence in chronic pain patients: a systematic review. Acta Anaesthesiol Scand 60(4):416–431PubMedCrossRefGoogle Scholar
  26. Tomaszewski M, White C, Patel P et al (2014) High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 100:855–861PubMedPubMedCentralCrossRefGoogle Scholar
  27. Viswanathan M, Golin CE, Jones CD et al (2012) Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 157:785–795PubMedCrossRefGoogle Scholar
  28. Zullig LL, Gellad WF, Moaddeb J et al (2015) Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence 9:139–149PubMedPubMedCentralCrossRefGoogle Scholar

Reporting Randomized Clinical Trials

  1. Calvert M, Brundage M, Jacobsen PB, Schünemann HJ, Efficace F (2013) The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. Health Qual Life Outcomes 11:184PubMedPubMedCentralCrossRefGoogle Scholar
  2. Camm CF, Agha RA, Edison E (2015) CONSORT adherence in journals is still far from perfect. Ann Surg 261:e38PubMedCrossRefGoogle Scholar
  3. Fuller T, Pearson M, Peters J, Anderson R (2015) What affects authors’ and editors’ use of reporting guidelines? Findings from an online survey and qualitative interviews. PLoS One 10:e0121585PubMedPubMedCentralCrossRefGoogle Scholar
  4. Grindlay DJ, Dean RS, Christopher MM, Brennan ML (2014) A survey of the awareness, knowledge, policies and views of veterinary journal Editors-in-Chief on reporting guidelines for publication of research. BMC Vet Res 10:10PubMedPubMedCentralCrossRefGoogle Scholar
  5. Nagendran M, Harding D, Teo W et al (2013) Poor adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacological treatments (NPT): a cross-sectional study. BMJ Open 3:e003898PubMedPubMedCentralCrossRefGoogle Scholar
  6. Strech D, Metz C, Knüppel H (2014) Do editorial policies support ethical research? A thematic text analysis of author instructions in psychiatry journals. PLoS One 9:e97492PubMedPubMedCentralCrossRefGoogle Scholar
  7. Thomas M, Schindler TM (2015) What defines good quality in a clinical study report? Ther Innovat Regul Sci 49:544–546CrossRefGoogle Scholar
  8. Turner L, Shamseer L, Altman DG et al (2012) Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev 11:MR000030Google Scholar
  9. Witkiewitz K, Finney JW, Harris AH, Kivlahan DR, Kranzler HR (2015) Guidelines for the reporting of treatment trials for alcohol use disorders. Alcohol Clin Exp Res 39:1571–1581PubMedPubMedCentralCrossRefGoogle Scholar
  10. Zarin DA, Tse T, Ross JS (2015) Trial-results reporting and academic medical centers. N Engl J Med 372:2371–2372PubMedCrossRefGoogle Scholar

General Readings

  1. Adler-Milstein J, Kvedar J, Bates DW (2014) Telehealth among US hospitals: several factors, including state reimbursement and licensure policies, influence adoption. Health Aff (Millwood) 33:207–215CrossRefGoogle Scholar
  2. Ali J, Andrews JE, Somkin CP, Rabinovich CE (2015) Harms, benefits, and the nature of interventions in pragmatic clinical trials. Clin Trials 12:467–475PubMedPubMedCentralCrossRefGoogle Scholar
  3. Ali J, Califf R, Sugarman J (2016) Anticipated ethics and regulatory challenges in PCORnet: The National Patient-centered Clinical Research Network. Account Res 23:79–96PubMedCrossRefGoogle Scholar
  4. Amur S, LaVange L, Zineh I, Buckman-Garner S, Woodcock J (2015) Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin Pharmacol Ther 98:34–46PubMedCrossRefGoogle Scholar
  5. Anderson ML, Griffin J, Goldkind SF et al (2015) The Food and Drug Administration and pragmatic clinical trials of marketed medical products. Clin Trials 12:511–519PubMedPubMedCentralCrossRefGoogle Scholar
  6. Ando Y, Uyama Y (2012) Multiregional clinical trials: Japanese perspective on drug development strategy and sample size for Japanese subjects. Biopharm Stat 22:977–987CrossRefGoogle Scholar
  7. Anker SD, Agewall S, Borggrefe M et al (2014) The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. Eur Heart J 35:2001–2009PubMedCrossRefGoogle Scholar
  8. Angevine PD, Berven S (2014) Health economic studies: an introduction to cost-benefit, cost-effectiveness, and cost-utility analyses. Spine (Phila Pa 1976) 39(22 Suppl 1):S9–S15CrossRefGoogle Scholar
  9. Antman EM, Bierer BE (2016) Standards for clinical research: keeping pace with the technology of the future. Circulation 133:823–825PubMedPubMedCentralCrossRefGoogle Scholar
  10. Asano K, Tanaka A, Sato T, Uyama Y (2013) Regulatory challenges in the review of data from global clinical trials: the PMDA perspective. Clin Pharmacol Ther 94:195–198PubMedCrossRefGoogle Scholar
  11. Baird LG, Banken R, Eichler HG et al (2014) Accelerated access to innovative medicines for patients in need. Clin Pharmacol Ther 96:559–571PubMedCrossRefGoogle Scholar
  12. Barratt RA, Bowens SL, McCune SK, Johannessen JN, Buckman SY (2012) The critical path initiative: leveraging collaborations to enhance regulatory science. Clin Pharmacol Ther 91:380–383PubMedCrossRefGoogle Scholar
  13. Bassani DG, Arora P, Wazny K et al (2013) Financial incentives and coverage of child health interventions: a systematic review and meta-analysis. BMC Public Health 13(Suppl 3):S30PubMedPubMedCentralCrossRefGoogle Scholar
  14. Bellows NM, Askew I, Bellows B (2015) Review of performance-based incentives in community-based family planning programmes. J Fam Plann Reprod Health Care 41:146–151PubMedCrossRefGoogle Scholar
  15. Bespalov A, Müller R, Relo AL, Hudzik T (2016) Drug tolerance: a known unknown in translational neuroscience. Trends Pharmacol Sci 37(5):364–378PubMedCrossRefGoogle Scholar
  16. Brumfield M (2014) The Critical Path Institute: transforming competitors into collaborators. Nat Rev Drug Discov 13:785–786PubMedCrossRefGoogle Scholar
  17. Califf RM (2014a) The new era of clinical research: using data for multiple purposes. Am Heart J 168:133–134PubMedCrossRefGoogle Scholar
  18. Califf RM (2014b) Patient-centered outcomes composites: a glimpse of the future. Circulation 130:1223–1224PubMedCrossRefGoogle Scholar
  19. Califf RM (2014c) The Patient-Centered Outcomes Research Network: a national infrastructure for comparative effectiveness research. N C Med J 75:204–210PubMedGoogle Scholar
  20. Califf RM, Ostroff S (2015) FDA as a catalyst for translation. Sci Transl Med 7:296ed9PubMedCrossRefGoogle Scholar
  21. Campbell F, Thokala P, Uttley LC et al (2014) Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy. Health Technol Assess 18:1–120CrossRefGoogle Scholar
  22. Cerreta F, Temple R, Asahina Y, Connaire C (2015) Regulatory activities to address the needs of older patients. J Nutr Health Aging 19:232–233PubMedCrossRefGoogle Scholar
  23. Darrow JJ, Avorn J, Kesselheim AS (2014) New FDA breakthrough-drug category: implications for patients. N Engl J Med 370:1252–1258PubMedCrossRefGoogle Scholar
  24. Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS (2015) Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med 372:279–286PubMedCrossRefGoogle Scholar
  25. Diaby V, Goeree R (2014) How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide. Expert Rev Pharmacoecon Outcomes Res 14:81–99PubMedCrossRefGoogle Scholar
  26. Doval DC, Shirali R, Sinha R (2015) Post-trial access to treatment for patients participating in clinical trials. Perspect Clin Res 6:82–85PubMedPubMedCentralCrossRefGoogle Scholar
  27. Eapen ZJ, Lauer MS, Temple RJ (2014) The imperative of overcoming barriers to the conduct of large, simple trials. JAMA 311:1397–1398PubMedCrossRefGoogle Scholar
  28. Eapen ZJ, Vavalle JP, Granger CB et al (2013) Rescuing clinical trials in the United States and beyond: a call for action. Am Heart J 165:837–847PubMedCrossRefGoogle Scholar
  29. Fox ER, Sweet BV, Jensen V (2014) Drug shortages: a complex health care crisis. Mayo Clin Proc 89:361–373PubMedCrossRefGoogle Scholar
  30. Franken M, Stolk E, Scharringhausen T, de Boer A, Koopmanschap M (2015) A comparative study of the role of disease severity in drug reimbursement decision making in four European countries. Health Policy 119:195–202PubMedCrossRefGoogle Scholar
  31. Gagnon MP, Desmartis M, Poder T, Witteman W (2014) Effects and repercussions of local/hospital-based health technology assessment (HTA): a systematic review. Syst Rev 3:129PubMedPubMedCentralCrossRefGoogle Scholar
  32. George AL Jr (2014) Use of contemporary genetics in cardiovascular diagnosis. Circulation 130:1971–1980PubMedPubMedCentralCrossRefGoogle Scholar
  33. Gilbert A, Sebag-Montefiore D, Davidson S, Velikova G (2015) Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic. Gynecol Oncol 136:429–439PubMedCrossRefGoogle Scholar
  34. Godman B, Finlayson AE, Cheema PK et al (2013) Personalizing health care: feasibility and future implications. BMC Med 11:179PubMedPubMedCentralCrossRefGoogle Scholar
  35. Hamburg MA, Rubin R (2015) Margaret A. Hamburg, MD, reflects on 6 years at FDA. JAMA 313:2309–2310PubMedCrossRefGoogle Scholar
  36. Heather EM, Payne K, Harrison M, Symmons DP (2014) Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models. Pharmacoeconomics 32:109–134PubMedCrossRefGoogle Scholar
  37. Herzberg D, Guarino H, Mateu-Gelabert P, Bennett AS (2016) Recurring epidemics of pharmaceutical drug abuse in America: time for an all-drug strategy. Am J Public Health 106:408–410PubMedPubMedCentralCrossRefGoogle Scholar
  38. Hess CN, Roe MT, Gibson CM et al (2014) Independent data monitoring committees: preparing a path for the future. Am Heart J 168:135–141PubMedPubMedCentralCrossRefGoogle Scholar
  39. Higgins A, Barnett J, Meads C, Singh J, Longworth L (2014) Does convenience matter in health care delivery? A systematic review of convenience-based aspects of process utility. Value Health 17:877–887PubMedCrossRefGoogle Scholar
  40. Hillblom D, Schueth A, Robertson SM, Topor L, Low G (2014) The impact of information technology on managed care pharmacy: today and tomorrow. J Manag Care Spec Pharm 20:1073–1079PubMedGoogle Scholar
  41. Hoppu K, Anabwani G, Garcia-Bournissen F et al (2012) The status of paediatric medicines initiatives around the world: what has happened and what has not? Eur J Clin Pharmacol 68:1–10PubMedCrossRefGoogle Scholar
  42. Hunter NL, O’Callaghan KM, Califf RM (2015) Engaging patients across the spectrum of medical product development: view from the US Food and Drug Administration. JAMA 314:2499–2500PubMedCrossRefGoogle Scholar
  43. Hutt PB, Temple R (2013) Commemorating the 50th anniversary of the Drug Amendments of 1962. Food Drug Law J 68:449–465PubMedGoogle Scholar
  44. Irvine JM, Hallvik SE, Hildebran C et al (2014) Who uses a prescription drug monitoring program and how? Insights from a statewide survey of Oregon clinicians. J Pain 15:747–755PubMedPubMedCentralCrossRefGoogle Scholar
  45. Jensen RE, Rothrock NE, DeWitt EM et al (2015) The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care. Med Care 53:153–159PubMedPubMedCentralCrossRefGoogle Scholar
  46. Jones CM, Lurie PG, Throckmorton DC (2016) Effect of US Drug Enforcement Administration’s rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing. JAMA Intern Med 176:399–402PubMedCrossRefGoogle Scholar
  47. Jönsson B (2015) Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development. Mol Oncol 9:1025–1033PubMedCrossRefGoogle Scholar
  48. Kaposy C (2014) Drugs, money, and power: the Canadian drug shortage. J Bioeth Inq 11:85–89PubMedCrossRefGoogle Scholar
  49. Kesselheim AS, Darrow JJ (2015) FDA designations for therapeutics and their impact on drug development and regulatory review outcomes. Clin Pharmacol Ther 97:29–36PubMedCrossRefGoogle Scholar
  50. Ketchersid T (2014) Health information technology: help or hindrance? Adv Chronic Kidney Dis 21:365–370PubMedCrossRefGoogle Scholar
  51. Khin NA, Yang P, Hung HM et al (2013) Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective. Clin Pharmacol Ther 94:230–242PubMedCrossRefGoogle Scholar
  52. Kleijnen S, Toenders W, de Groot F et al (2015) European collaboration on relative effectiveness assessments: what is needed to be successful? Health Policy 119:569–576PubMedCrossRefGoogle Scholar
  53. Kok L, Boyle S, Lammers M, Tempelman C (2015) Remuneration of medical specialists. Drivers of the differences between six European countries. Health Policy 119:1188–1196PubMedCrossRefGoogle Scholar
  54. Lahey T (2013) The ethics of clinical research in low- and middle-income countries. Handb Clin Neurol 118:301–313PubMedCrossRefGoogle Scholar
  55. Lanthier M, Miller KL, Nardinelli C, Woodcock J (2013) An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987–2011. Health Aff (Millwood) 32:1433–1439CrossRefGoogle Scholar
  56. Laugesen MJ (2014) The resource-based relative value scale and physician reimbursement policy. Chest 146:1413–1419PubMedCrossRefGoogle Scholar
  57. Lewis JH (2015) The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin Gastroenterol Hepatol 13:2173–2189PubMedCrossRefGoogle Scholar
  58. Loke YK (2014) Use of databases for clinical research. Arch Dis Child 99:587–589PubMedCrossRefGoogle Scholar
  59. Lopes P, Nunes T, Campos D et al (2013) Gathering and exploring scientific knowledge in pharmacovigilance. PLoS One 8:e83016PubMedPubMedCentralCrossRefGoogle Scholar
  60. Lurie P, Chan-Tack KM, Woodcock J (2015) Expanded access to investigational drugs. N Engl J Med 372:1473PubMedCrossRefGoogle Scholar
  61. Manolis E, Koch A, Deforce D, Vamvakas S (2015) The European Medicines Agency experience with biomarker qualification. Methods Mol Biol 1243:255–272PubMedCrossRefGoogle Scholar
  62. Mihajlović J, Dolk C, Tolley K, Simoens S, Postma MJ (2015) Reimbursement of targeted cancer therapies within 3 different European health care systems. Clin Ther 37:474–480PubMedCrossRefGoogle Scholar
  63. Milne CP (2014) Prospects for rapid advances in the development of new medicines for special medical needs. Clin Pharmacol Ther 95:98–109PubMedCrossRefGoogle Scholar
  64. Moore TJ, Furberg CD (2014) Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008. JAMA Intern Med 174:90–95PubMedCrossRefGoogle Scholar
  65. Murthy S, Mandl KD, Bourgeois FT (2015) Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013. Health Res Policy Syst 13:28PubMedPubMedCentralCrossRefGoogle Scholar
  66. O’Neill RT, Temple R (2012) The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin Pharmacol Ther 91:550–554PubMedCrossRefGoogle Scholar
  67. Otsubo Y, Ishiguro A, Uyama Y (2013) Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developments. Pharmacogenomics 14:195–203PubMedCrossRefGoogle Scholar
  68. Palmer KS, Agoritsas T, Martin D et al (2014) Activity-based funding of hospitals and its impact on mortality, readmission, discharge destination, severity of illness, and volume of care: a systematic review and meta-analysis. PLoS One 9:e109975PubMedPubMedCentralCrossRefGoogle Scholar
  69. Pokorney SD, O’Brien EC, Granger CB (2016) Assessing generalizability of trial results in general practice. Eur Heart J 37(14):1154–1157PubMedCrossRefGoogle Scholar
  70. Robles-Diaz M, Lucena MI, Kaplowitz N, Spanish DILI Registry, SLatinDILI Network, Safer and Faster Evidence-based Translation Consortium et al (2014) Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 147:109–118.e5Google Scholar
  71. Sachs-Barrable K, Conway J, Gershkovich P, Ibrahim F, Wasan KM (2014) The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases. Drug Dev Ind Pharm 40:1429–1434PubMedCrossRefGoogle Scholar
  72. Selker HP, Oye KA, Eichler HG et al (2014) A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials. Clin Pharmacol Ther 95:147–153PubMedCrossRefGoogle Scholar
  73. Stolker JM, Spertus JA, Cohen DJ et al (2014) Rethinking composite end points in clinical trials: insights from patients and trialists. Circulation 130:1254–1261PubMedPubMedCentralCrossRefGoogle Scholar
  74. Smith RJ, Kilaru AS, Perrone J et al (2015b) How, why, and for whom do emergency medicine providers use prescription drug monitoring programs? Pain Med 16:1122–1131PubMedPubMedCentralCrossRefGoogle Scholar
  75. Tanimoto T (2015) A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan. Drug Des Devel Ther 9:1877–1888PubMedPubMedCentralCrossRefGoogle Scholar
  76. Tenaerts P, Madre L, Archdeacon P, Califf RM (2014) The Clinical Trials Transformation Initiative: innovation through collaboration. Nat Rev Drug Discov 13:797–798PubMedCrossRefGoogle Scholar
  77. Van der Wees PJ, der Nijhuis-van der Sanden MW, Ayanian JZ et al (2014a) Integrating the use of patient-reported outcomes for both clinical practice and performance measurement: views of experts from 3 countries. Milbank Q 92:754–775CrossRefGoogle Scholar
  78. Van der Wees PJ, Nijhuis-van der Sanden MW, van Ginneken E et al (2014b) Governing healthcare through performance measurement in Massachusetts and the Netherlands. Health Policy 116:18–26PubMedCrossRefGoogle Scholar
  79. Vickers AJ (2014) Clinical trials in crisis: four simple methodologic fixes. Clin Trials 11:615–621PubMedPubMedCentralCrossRefGoogle Scholar
  80. Vitiello B (2015) Practical clinical trials in psychopharmacology: a systematic review. J Clin Psychopharmacol 35:178–183PubMedPubMedCentralCrossRefGoogle Scholar
  81. Ward DJ, Martino OI, Simpson S, Stevens AJ (2013) Decline in new drug launches: myth or reality? Retrospective observational study using 30 years of data from the UK. BMJ Open 3:e002088PubMedPubMedCentralCrossRefGoogle Scholar
  82. Ward DJ, Slade A, Genus T, Martino OI, Stevens AJ (2014) How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001–2012. BMJ Open 4:e006235PubMedPubMedCentralCrossRefGoogle Scholar
  83. Weinstein RS, Lopez AM, Joseph BA et al (2014) Telemedicine, telehealth, and mobile health applications that work: opportunities and barriers. Am J Med 127:183–187PubMedCrossRefGoogle Scholar
  84. Wittes J, Schactman M (2014) On independent data monitoring committees in oncology clinical trials. Chin Clin Oncol 3:40PubMedGoogle Scholar
  85. Woodcock J (2014b) Drug development in serious diseases: the new “breakthrough therapy” designation. Clin Pharmacol Ther 95:483–485PubMedCrossRefGoogle Scholar
  86. Xie A, Gao J, Xu L, Meng D (2014) Shared mechanisms of neurodegeneration in Alzheimer’s disease and Parkinson’s disease. Biomed Res Int 2014:648740PubMedPubMedCentralGoogle Scholar
  87. Yé M, Aninanya GA, Sié A et al (2014) Establishing sustainable performance-based incentive schemes: views of rural health workers from qualitative research in three sub-Saharan African countries. Rural Remote Health 14:2681PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • J. Rick Turner
    • 1
  • Dilip R. Karnad
    • 2
  • Snehal Kothari
    • 3
  1. 1.Cardiac Safety Services QuintilesDurhamUSA
  2. 2.Research TeamCardiac Safety Services QuintilesMumbaiIndia
  3. 3.Cardiac Safety Services Global HeadCardiac Safety Center of Excellence QuintilesMumbaiIndia

Personalised recommendations